Clinical Case Reports (Jul 2022)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience

  • Alicia Roldán Pérez,
  • Juan Andrés Vázquez Paganini,
  • M. José Penalva Moreno,
  • Eugenio Giménez Mesa,
  • Alba Sara Vilches Moreno,
  • Claudia Nuñez‐Torrón Stock,
  • Regina Herráez García

DOI
https://doi.org/10.1002/ccr3.6116
Journal volume & issue
Vol. 10, no. 7
pp. n/a – n/a

Abstract

Read online

Abstract We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well‐tolerated in 62.5% of the patients. Ven/HMA provides a benefit particularly when used in patients without prior HMA exposure.

Keywords